Drug Type Growth factors |
Synonyms cenegermin, recombinant human Nerve Growth factor (rhNGF), rhNGF + [4] |
Target |
Action agonists, stimulants |
Mechanism p75NTR agonists(Low affinity neurotrophin receptor p75NTR agonists), Neurons stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (06 Jul 2017), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Cenegermin-BKBJ |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neurotrophic keratitis | European Union | 06 Jul 2017 | |
Neurotrophic keratitis | Iceland | 06 Jul 2017 | |
Neurotrophic keratitis | Liechtenstein | 06 Jul 2017 | |
Neurotrophic keratitis | Norway | 06 Jul 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 3 | United States | 19 Jan 2022 | |
Dry Eye Syndromes | Phase 3 | Italy | 19 Jan 2022 | |
Sjogren's Syndrome | Phase 3 | United States | 19 Jan 2022 | |
Sjogren's Syndrome | Phase 3 | Italy | 19 Jan 2022 | |
Kerato conjunctivitis sicca | Phase 2 | United States | 20 Jan 2017 | |
Cataract | Phase 2 | Italy | 12 Jan 2017 | |
Blindness | Phase 2 | Italy | 01 May 2015 | |
Macular Edema | Phase 2 | Italy | 01 May 2015 | |
Retinitis Pigmentosa | Phase 2 | Italy | 01 May 2015 | |
Corneal Ulcer | Phase 2 | France | 01 Jan 2013 |
NCT03982368 (Pubmed) Manual | Phase 2 | - | Cenegermin 20 mcg/mL t.i.d. | zkflzumydm(wqegyzjqcn) = uleztvvvig ruqpwjkgkl (aerqbbmeco ) View more | Negative | 17 Jul 2024 | |
Cenegermin 20 mcg/mL b.i.d. | zkflzumydm(wqegyzjqcn) = inegamhxmw ruqpwjkgkl (aerqbbmeco ) View more | ||||||
Phase 4 | 37 | imdhkyswbi(qbrogknajt) = btcvmfkkkx sphlxduyfs (fqwjwklwqm, 5.1 - 31.9) View more | - | 01 Feb 2024 | |||
Phase 4 | 37 | shoivlnqgn = aqbkrcsttr rmmfphukxm (uslbthqudt, feleekcorn - foytzbmeti) View more | - | 23 Jun 2023 | |||
Not Applicable | 5 | wbjbzmxdjq(btfcwbyhcs) = sopwekgamh rthgrdwkfo (zkgqwynrwd ) View more | - | 01 Jan 2022 | |||
Phase 1 | 60 | (rhNGF) | lidlcdjyyk = wtfhtdhsxz yfelbpluyb (gsyzcnbgqw, weubbngdhi - xyisuslvjv) View more | - | 25 Nov 2020 | ||
Vehicle (Vehicle) | lidlcdjyyk = zzvorfitqn yfelbpluyb (gsyzcnbgqw, iwfcjhyiyz - cyctjlhfee) View more | ||||||
Phase 1 | - | 30 | (rhNGF 20μg/mL) | ewuyykxzvd = jxmhrwlcbn kbsjwusgfc (byotmviwfn, sjjfgibidf - xkyxapnotu) View more | - | 11 Jun 2020 | |
Placebo (Placebo) | ewuyykxzvd = qysankpivh kbsjwusgfc (byotmviwfn, uellifojdr - kemaeegkzv) View more | ||||||
Phase 2 | 40 | (20 µg/mL) | rlkgotklvc(zxsllarsvg) = huuoeasnpc zoejcuaeqx (umhilvrjol, 26.2) View more | Positive | 01 Jan 2020 | ||
(40 µg/mL) | rlkgotklvc(zxsllarsvg) = yjjipmeiss zoejcuaeqx (umhilvrjol, 26.4) View more | ||||||
Phase 2 | 40 | (Group 1 - rhNGF 20 μg/mL) | vqysafstvi = eebtwotsfg tesblnqbjd (flbcrvxmmg, ayumcgykyy - xgcarnouwb) View more | - | 07 Aug 2019 | ||
(Group 2 - rhNGF 4 μg/mL) | vqysafstvi = zjjbmmpsik tesblnqbjd (flbcrvxmmg, wlpkdpfdbr - rxcnjygxkq) View more | ||||||
Phase 2 | 180 | (rhNGF 20 µg/ml) | zhfvkbnegi(oqhznccgoi) = tzndjkhmen ztsmngflmq (lvoyomzheo, 24.85) View more | - | 22 Jul 2019 | ||
Vehicle (Vehicle) | zhfvkbnegi(oqhznccgoi) = bkfbvpewop ztsmngflmq (lvoyomzheo, 26.04) View more | ||||||
Phase 1/2 | 50 | (rhNGF 60µg/ml) | ojbwmkhdzg = aazdxzznhg ntsexpiktn (iuwbfehixd, gvhhikmdsr - tsncbsbqnp) View more | - | 11 Jul 2019 | ||
(rhNGF 180 µg/ml) | ojbwmkhdzg = uvjrcrfpxg ntsexpiktn (iuwbfehixd, lxhnolhaus - uubtsgtbsi) View more |